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OBJECTIVES We sought to determine the efficacy and safety of platelet glycoprotein IIb/IIIa receptor (GP
IIb/IIIa) blockade with abciximab in women undergoing percutaneous coronary intervention.
BACKGROUND Although gender differences in response to platelet glycoprotein IIb/IIIa receptor blockade
have been described, there have been no large clinical studies to assess these differences.
METHODS Outcomes were determined using meta-analysis technique.
RESULTS In the pooled analysis, the primary end point of death, myocardial infarction (MI) or urgent
revascularization within 30 days was reduced from 11.3% to 5.8% (p , 0.001) in men and
from 12.7% to 6.5% (p , 0.001) in women treated with abciximab. At six months, death, MI
or urgent revascularization was reduced from 14.1% to 8.3% (p , 0.001) in men and 16.0%
to 9.9% (p , 0.001) in women receiving abciximab. At one year, mortality was reduced from
2.7% to 1.9% (p 5 0.06) in men and 4.0% to 2.5% (p 5 0.03) in women treated with
abciximab. Major bleeding events occurred in 2.9% versus 3.0% (p 5 0.96) of women and
2.7% versus 1.3% (p 5 0.003) of men treated with placebo versus abciximab, respectively.
Minor bleeding events occurred in 4.7% versus 6.7% (p 5 0.01) of women and 2.3% versus
2.2% (p 5 0.94) of men treated with placebo versus abciximab, respectively.
CONCLUSIONS This pooled analysis demonstrated no gender difference in protection from major adverse
outcomes with GP IIb/IIIa inhibition with abciximab. Although women had higher rates of
both major and minor bleeding events with abciximab compared with men, major bleeding
in women was similar with and without abciximab. There was a small increased risk of minor
bleeding with abciximab in women. (J Am Coll Cardiol 2000;36:381–6) © 2000 by the
American College of Cardiology
Atherosclerotic heart disease is the leading cause of mor-
bidity and mortality in women in the U.S. (1–2). Percuta-
neous coronary revascularization remains the most fre-
quently performed procedure in women over 65 years of age
(3). However, women may have a higher incidence of poor
outcome after percutaneous coronary intervention (PCI)
compared with men (4–5). Mechanisms responsible for
these findings may include older age, higher incidence of
comorbidities and smaller coronary arteries and body size in
women (6). However, there has been an interesting body of
literature reporting increased platelet function in women as
another mechanism explaining the “gender gap” (7–16),
suggesting that women would benefit more than men from
glycoprotein IIb/IIIa (GP IIb/IIIa) blockade.
Although the role of GP IIb/IIIa blockade during coro-
nary intervention has been established, there has been some
conflicting data regarding the use of these agents in women.
This current study examines the aggregate data from the
three large randomized trials of abciximab (ReoPro, Cen-
tocor, Malvern, Pennsylvania), Evaluation of 7E3 for the
Prevention of Ischemic Complications (EPIC, 14), Evalu-
ation in Percutaneous Transluminal Coronary Angioplasty
to Improve Long-Term Outcome with Abciximab GP
IIb/IIIa Blockade (EPILOG, 15) and Evaluation of Platelet
IIb/IIIa Inhibitor for Stenting (EPISTENT, 16) in the
setting of PCI to evaluate the influence of gender on
outcome and treatment effect with GP IIb/IIIa blockade.
METHODS
Study group. Prospective data were collected from patients
undergoing PCI enrolled in the EPIC, EPILOG and
EPISTENT trials (17–19). The details of the inclusion and
exclusion criteria and trial designs have been published
elsewhere. Briefly, the inclusion criteria for EPIC included:
1) acute myocardial infarction (MI) with primary or rescue
angioplasty within 12 h of symptom onset; 2) early postin-
farction angina or unstable angina with electrocardiographic
evidence of ischemia; or 3) high-risk lesion morphology
with advanced age, female gender or diabetes mellitus.
There were 392 women and 1,012 men enrolled in the trial
who were treated with either placebo or the bolus and
infusion regimen of abciximab. Inclusion criteria for
EPILOG included elective or urgent percutaneous coronary
revascularization, excluding patients with acute MI or un-
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stable angina according to the EPIC criteria. There were
780 women and 2,012 men enrolled in the trial. Inclusion
criteria for EPISTENT were patients referred for elective or
urgent PCI who were suitable candidates for either conven-
tional angioplasty or coronary stent implantation. There
were 599 women and 1,800 men enrolled in the trial.
Overall, there were 6,595 patients, of whom 1,771 (26.9%)
were women and 4,824 (73.1%) were men.
Protocols. In the three trials, all patients were treated with
aspirin. In EPIC, patients were randomized to placebo,
abciximab bolus only (0.25 mg/kg) or abciximab bolus
followed by a 12 h infusion (10 mg/min). Heparin was given
in all three arms with initial bolus dose of 10,000 to
12,000 U. In the EPILOG trial, patients were randomized
to placebo with standard-dose, weight-adjusted heparin
(100 U/kg, target activated clotting time [ACT] # 300),
abciximab bolus followed by 12 h infusion (0.125 mg/kg/
min, maximum 10 mg/min) with standard-dose, weight-
adjusted heparin or abciximab bolus and infusion with
low-dose, weight-adjusted heparin (70 U/kg, ACT $ 200).
In EPISTENT, patients were randomized to stent and
placebo with standard-dose, weight-adjusted heparin, stent
and abciximab bolus and infusion with low-dose, weight-
adjusted heparin or balloon angioplasty and abciximab bolus
and infusion with low-dose, weight-adjusted heparin.
Study end points. The primary end point for these trials
was a composite of death from all cause, MI or reinfarction
or severe myocardial ischemia requiring urgent revascular-
ization by either PCI or coronary artery bypass grafting
(CABG) within 30 days after randomization. A second end
point was a composite of death, MI or urgent revascular-
ization within six months after randomization. For the
long-term follow-up at one year, mortality was used. End
point classifications of clinical events committees, blinded to
treatment assignment, were used for the final analysis. An
end point of in-hospital, MI was defined by one of two
criteria: new, clinically significant Q waves in two or more
contiguous electrocardiographic leads or elevation in creat-
ine kinase or its MB isoenzyme to at least three times the
upper limit of normal. After discharge from the hospital,
MI was defined by the occurrence of new Q waves in two or
more contiguous electrocardiographic leads or an elevation
of creatine kinase or its MB isoenzyme to more than twice
the upper limit of normal. The MB isoenzyme value was
used if it was available; if not, the total creatine kinase value
was used.
Bleeding events were classified as major or minor accord-
ing to the criteria used by the Thrombolysis in Myocardial
Infarction Study Group (17). Hemorrhage was defined as
major if there was a reduction of hemoglobin of more than
5 g/dl (or $15% in hematocrit) or any intracranial bleeding
(17). Minor bleeding was defined as observed blood loss
with reduction in hemoglobin of more than 3 g/dl but less
than or equal to 5 g/dl (or 10–15% reduction in hematocrit)
if there was spontaneous gross hematuria or hematemesis,
even if the hemoglobin or hematocrit drop was less or equal
to 3 g/dl or less than 10% respectively or, if there was no
observed blood loss, a reduction of more than 4 g/dl in
hemoglobin or 12% or more in hematocrit (17). Hemoglo-
bin and hemotocrit were measured before and 12 to 36 h
after initiation of the study agent and at the time of
discharge (14–16). All suspected occurrences of stroke or
intracranial hemorrhage were adjudicated by an indepen-
dent neurologist.
Statistical analysis. Pooled abciximab bolus and infusion
versus placebo groups were analyzed by gender. Individual
patient data for all three trials were combined. We excluded
the abciximab bolus only group because this dosing was
found to be ineffective in reducing ischemic complications
and was used only in the EPIC trial. Efficacy was analyzed
on an intention-to-treat basis with use of Pearson’s chi-
square test and Mantel-Haenszel statistics. A combination
of 13 baseline and angiographic characteristics, in addition
to gender, was used for multivariate logistic regression
modeling for the combined cohort of data. These included
age, prior PCI, prior CABG, hypertension, diabetes, smok-
ing status, history of congestive heart failure (CHF), prior
MI, American College of Cardiology/American Heart As-
sociation (ACC/AHA) type B2 or C lesions, thrombus,
bypass graft lesions and treatment with abciximab.
The separate analysis of bleeding by gender compared
pooled individual patient data from EPILOG and
EPISTENT who received low-dose, weight-adjusted hep-
arin and abciximab to those patients who received standard-
dose heparin without abciximab. We excluded the standard-
dose, heparin arms with abciximab in EPIC and EPILOG,
as the EPILOG trial showed that low-dose, weight-
adjusted heparin was as effective as standard-dose, weight-
adjusted heparin during abciximab therapy but with fewer
bleeding complications. A combination of 20 demographic
and angiographic characteristics, in addition to gender, was
used for multivariate logistic regression modeling. These
Abbreviations and Acronyms
ACC/AHA 5 American College of
Cardiology/American Heart Association
ACT 5 activated clotting time
CABG 5 coronary artery bypass graft
CHF 5 congestive heart failure
EPIC 5 Evaluation of 7E3 for the Prevention of
Ischemic Complications trial
EPILOG 5 Evaluation of Percutaneous
Transluminal Coronary Angioplasty to
Improve Long-Term Outcome with
Abciximab Glycoprotein IIb/IIIa
Blockade trial
EPISTENT 5 Evaluation of Platelet IIb/IIIa Inhibitor
for Stenting trial
GP IIb/IIIa 5 Glycoprotein IIb/IIIa receptor
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
PTT 5 partial thromboplastin time
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included age, body weight, diabetes, use of abciximab,
hypertension, use of ticlopidine or aspirin or other antico-
agulant, race, smoking status, residency of the patient and
activated clotting time. The adjusted odds ratios, confidence
intervals and p values for all significant variables are re-
ported.
RESULTS
The demographics of the pooled gender groups are shown
in Table 1. Women were, on the average, five years older
and had more comorbidities than their male counterparts,
including hypertension, CHF and diabetes. However, men
were more likely to have had prior PCIs, CABG and a
history of MI and smoking. Overall, women had slightly
fewer type B2 lesions but more lesions with acute angula-
tions. However, men had more thrombus-containing and
vein graft lesions.
Pooled analysis. The primary end point—a composite
death, MI or need for urgent revascularization in the first 30
days—was reduced from 11.3% to 5.8% (49% relative risk
reduction, p , 0.001) in men and from 12.7% to 6.5% (49%
relative risk reduction, p , 0.001) in women treated with
abciximab (Fig. 1). For men and women treated with
abciximab, there was no statistical difference in the 30-day
end point, 5.8% versus 6.5% (p 5 0.40), respectively. There
was no gender difference in the magnitude of treatment
effect achieved with abciximab in the pooled analysis or in
the individual trials at 30 days (Table 2). The treatment
effect of abciximab was maintained to six months and to one
year in both men and women. At six months, death, MI or
urgent revascularization was reduced from 14.1% to 8.3%
(relative risk reduction of 41%, p , 0.001) in men and
16.0% to 9.9% (relative risk reduction 38%, p 5 0.01) in
women receiving abciximab. There was no difference in
treatment benefit with abciximab between men and women
at six months. At one year, mortality was reduced from 2.7%
to 1.9% (30% relative risk reduction, p 5 0.06) in men and
4% to 2.5% (38% relative risk reduction, p 5 0.03) in
women treated with abciximab at one year. Clinical benefit
with GP IIb/IIIa blockade with abciximab was independent
of gender. By multivariate logistic regression, abciximab use
was independently associated with improved outcome at 30
days, six months and one year (Fig. 2). The factors associ-
ated with poor outcome were hypertension, history of MI,
Figure 1. Primary composite end point of death, MI or urgent revascular-
ization at 30 days. p , 0.001 for both male and female patients. MI 5
myocardial infarction; Revasc 5 revascularization.
Table 1. Demographics
Men
(n 5 4,824)
Women
(n 5 1,771) p Value
Age (yrs)* 58.5 6 10.7 62.9 6 10.4 , 0.001
Caucasians (%) 91.1 88.3 , 0.001
Prior PCI (%) 22.0 18.7 0.004
Prior CABG (%) 12.7 9.6 , 0.001
Hypertension (%) 52.3 65.3 , 0.001
CHF (%) 5.3 9.4 , 0.001
Diabetes (%) 19.4 30.3 , 0.001
Prior MI (%) 53.8 42.6 , 0.001
Worst lesion (%)
Type B2 57.4 55.7 0.03
Type C 17.0 15.1
Length (%)
10–20 mm 38.7 36.5 0.18
.20 mm 9.6 9.1
Eccentricity (%) 66.8 65.8 0.47
Lesion angulation (%)
45–90 14.9 17.1
.90 1.4 2.1 0.02
Irregular contour (%) 53.6 48.7 , 0.001
Ostial (%) 8.1 7.7 0.61
Calcification (%) 10.7 12.0 0.14
Thrombus (%) 17.9 14.8 0.003
Bifurcation (%) 7.4 7.1 0.40
Bypass grafts (%) 2.6 1.3 , 0.001
*Age 6 standard deviation.
CABG 5 coronary artery bypass graft; CHF 5 congestive heart failure; MI 5
myocardial infarction; PCI 5 percutaneous coronary intervention.
Table 2. Thirty-Day and Six-Month Primary End Point of Death, MI or Urgent Revascularization Hazard Ratios for Each Trial
Comparing Abciximab Versus Placebo
30 days 6 months
Placebo Abciximab OR (95% CI) p Value Placebo Abciximab OR p Value
EPIC Men (%) 12.1 7.7 0.63 (0.42, 0.93) 0.02 16.6 11.4 0.66 (0.47, 0.93) 0.02
EPIC Women (%) 13.7 7.4 0.52 (0.28, 0.98) 0.05 19.2 12.0 0.59 (0.36, 1.00) 0.05
EPILOG Men (%) 11.3 5.0 0.43 (0.31, 0.60) , 0.001 14.4 8.0 0.53 (0.40, 0.69) , 0.001
EPILOG Women (%) 12.8 5.9 0.46 (0.28, 0.75) 0.002 15.5 9.4 0.58 (0.38, 0.88) 0.01
EPISTENT Men (%) 10.5 5.9 0.55 (0.39, 0.77) 0.001 11.6 7.3 0.61 (0.44, 0.83) 0.002
EPISTENT Women (%) 11.7 6.9 0.57 (0.33, 0.99) 0.05 13.6 9.5 0.67 (0.41, 1.10) 0.11
CI 5 confidence interval; OR 5 odds ratio.
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ACC/AHA type B2 or C lesions and thrombus containing
lesions.
Complications. Major bleeding events occurred in 2.9%
versus 3.0% (p 5 0.96) of women and 2.7% versus 1.3%
(p 5 0.003) of men treated with placebo versus abciximab,
respectively. Minor bleeding events occurred in 4.7% versus
6.7% (p 5 0.017) of women and 2.3% versus 2.2% (p 5
0.94) of men treated with placebo versus abciximab, respec-
tively (Table 3). However, there were no differences in rates
of intracranial bleeding for women (0.0% vs. 0.3%, p 5 NS)
or men (0.1% vs. 0.1%, p 5 NS) treated with placebo versus
abciximab. The overall rates of bleeding and the gradient of
bleeding risk with abciximab were markedly less in the
treatment arms of EPILOG and EPISTENT, using re-
duced and weight-adjusted heparin dosing. Women had
higher rates of major and minor bleeding complications
with abciximab than men. Activated clotting time for
women treated with abciximab were slightly higher than
men treated with abciximab, 330 versus 326 (p 5 0.3).
However, the rate of major bleeding among women treated
with abciximab was 3% compared with 1.3% in men (p 5
0.004). Also, the rate of minor bleeding among women
treated with abciximab was 6.7% versus 2.2% in men (p ,
0.001, Fig. 3). While women had higher rates of bleeding
with abciximab compared with men, they also had a higher
rate of minor bleeding complications without abciximab
than men, 4.7% versus 2.3% (p 5 0.01) even though they
had lower activated clotting time than men 368 versus 376
(p 5 0.01) (Table 3).
A multivariate logistic regression model was developed
using 20 clinical variables to determine the risk of bleeding
(Fig. 4). Predictor of both major and minor bleeding was
older age. However, there was a significant interaction
between abciximab treatment, gender and bleeding out-
come. Abciximab use, gender, body weight, race, smoking
status and the use of aspirin, Ticlopidine or clopidogrel did
not increase the risk of bleeding.
DISCUSSION
Summary. Our study examined collective data from three
large randomized trials that enrolled, in aggregate, 6,595
patients undergoing percutaneous coronary revasculariza-
tion. While women had more comorbidities, they derived
equivalent treatment benefit with abciximab during PCI as
did men at 30 days, six months and one year. We did not
observe gender differences in clinical outcome after percu-
taneous intervention. The reduction in death, MI or urgent
revascularization with abciximab was not gender specific at
any time point.
However, women had a higher rate of major and minor
bleeding with abciximab and heparin, even with low-dose,
weight-adjusted heparin dosing compared with men. In the
Figure 2. Clinical predictors of outcome after percutaneous coronary
revascularization for the overall cohort. HTN 5 hypertension; MI 5
myocardial infarction.
Figure 3. Major and minor bleeding event rates for patients treated with
abciximab. p 5 0.004 for major bleeding event; p , 0.001 for minor
bleeding events.
Table 3. Bleeding Complications by Gender for Patients Receiving Abciximab
Men Women
p Value† p Value‡
Placebo
(n 5 1,277)
Abciximab
(n 5 1,865) p Value*
Placebo
(n 5 471)
Abciximab
(n 5 660)
Major (%) 2.7 1.3 0.003 2.9 3.0 0.96 0.004
Minor (%) 2.3 2.2 0.94 4.7 6.7 0.17 , 0.001
Non-CABG major (%) 0.8 0.7 0.64 1.8 1.4 0.61 0.08
Non-CABG minor (%) 2.2 2.2 0.97 4.3 6.6 0.11 , 0.001
Intracranial (%) 0.0 0.1 0.41 0.0 0.0 1.00 0.55
p value* 5 comparing male patients receiving placebo vs. abciximab; p value† 5 comparing female patients receiving placebo vs. abciximab; p value‡ 5 comparing male vs. female
patients receiving abciximab.
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multivariate logistic regression model, there was an interac-
tion between abciximab treatment, gender and bleeding
complications. Gender differences in bleeding complications
after PCI have been described (18). A possible explanation
may be due to gender specific response to anticoagulants. A
prior work has shown increased partial thromboplastin time
(PTT) for women with heparin, even after weight-adjusted
dosing, suggesting an increased sensitivity to heparin among
women (19).
Gender differences platelet aggregation. Platelet aggre-
gation at the site of plaque rupture is a dominant feature in
the pathophysiology of acute coronary syndromes and com-
plications of percutaneous coronary revascularization. The
final common pathway of platelet aggregation is the binding
of fibrinogen to GP IIb/IIIa receptors on the surface of
activated platelets leading to platelet thrombus (20). Several
studies have suggested intergender differences in platelet
response and reactivity, including a greater sensitivity of the
platelets of women to aggregating stimuli (7,8,13). Re-
cently, Faraday and associates (12) showed that platelets of
women are capable of converting a greater proportion of
available GP IIb/IIIa receptors to an activated state in
response to both weak and strong agonists than are those of
men. These investigators demonstrated a 50% to 80%
increase in the number of activated receptor sites in women
compared with men given the same agonist. Because
women have more platelet reactivity, it is possible that they
would derive greater benefit from a potent platelet inhibitor.
In a small study, Goldschmidt-Clermont and associates (21)
reported a greater reduction of ischemic events in female
patients with acute coronary syndromes receiving eptifi-
batide, a GP IIb/IIIa inhibitor, than in men. While aspirin
was adequate in reducing the ischemic state in men, women
derived benefit only with GP IIb/IIIa inhibitor. This
observation has not been confirmed, however, in large-scale
trials of eptifibatide (22), tirofiban (23,24) or lamifiban (25).
Moreover, the recent Platelet Glycoprotein IIb/IIIa in
Unstable Angina: Receptor Suppression Using Integrilin
Therapy (PURSUIT) trial showed that benefit with eptifi-
batide among patients with acute coronary syndromes was
not observed in women treated outside North America (22).
These conflicting findings have led to some confusion
regarding the role of GP IIb/IIIa blockade in women.
Although there is an increased risk of minor bleeding
with abciximab in women, these data demonstrate a signif-
icant treatment benefit with abciximab in reduction in
death, MI and urgent revascularization, perhaps suggesting
that all patients, regardless of gender, will derive important
clinical benefit from abciximab.
Study limitations. Our study has a few key limitations.
This was a retrospective analysis. Also, we did not perform
a formal utility analysis. Lastly, in both the EPILOG and
EPISTENT trials, there was a strict guideline for ACT and
PTT range, for vascular access sites, as well as emphasis on
early sheath removal; therefore, many of the variables that
have been shown to affect bleeding complications were
tightly controlled. Therefore, we lacked sufficient statistical
power to perform detailed analysis on bleeding based on
ACT or PTT range.
Conclusions. Over 240,000 women will receive either
coronary stents or angioplasty this year. There has been
some reluctance to use GP IIb/IIIa inhibition in women due
to a perceived increased risk of complications and question-
able benefit. Our study shows that women derive equivalent
short- and long-term benefit from abciximab during percu-
taneous coronary intervention as do men. Although women
had higher rates of both major and minor bleeding than did
men with abciximab, major bleeding in women was similar
with and without abciximab. A small increase in minor
bleeding was observed with abciximab in women. The
challenge lies ahead for optimizing the safety of percutane-
ous coronary intervention in women. Possible approaches
for the future include combining GP IIb/IIIa blockade with
other inhibitors of the thrombin cascade, which may present
less of a hemorrhagic risk, such as bivalirudin or low
molecular weight heparin.
Reprint requests and correspondence to: Dr. A. Michael Lin-
coff, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid
Ave, Cleveland, Ohio 44195. E-mail: lincofa@ccf.org.
REFERENCES
1. Wenger NK. Coronary heart disease: an older woman’s major health
risk. Br Med J 1997;313:1085–90.
2. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The
primary prevention of coronary heart disease in women. N Engl J Med
1995;332:1758–66.
3. National Center for Health Statistics. Health, United States, 1996–97
and Injury Chartbook. Washington, DC; Government Printing Of-
fice, 1997.
4. Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre
KM. Results of percutaneous transluminal coronary angioplasty in
women. Circulation 1993;87:720–7.
5. Malenka DJ, O’connor GT, Quinton H, et al. Differences in outcomes
between women and men associated with percutaneous transluminal
coronary angioplasty. Circulation 1996;94 Suppl II:II99–104.
6. Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous
Figure 4. Clincal predictors of bleeding complications using low-dose
heparin arm of EPILOG and the entire EPISTENT cohort.
385JACC Vol. 36, No. 2, 2000 Cho et al.
August 2000:381–6 Women and Abciximab
transluminal coronary angioplasty in women compared to men. J Am
Coll Cardiol 1994;24:81–90.
7. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human
platelet aggregation. Nature 1975;253:355–7.
8. Reading HW, Rosie R. Age and sex differences related to platelet
aggregation. Biochem Soc Transcript 1980;8:180–1.
9. Danielsen R, Onundarson PT, Thors H, Vidarsson B, Morrissey JH.
Activated and total coagulation factor VII and fibrinogen in coronary
artery disease. Scad Cardiol J 1998;32:87–95.
10. Michimata T, Imamura M, Mizuma H, Murakami M, Iriuchijima T.
Sex and age differences in soluble guanylate cyclase activity in human
platelets. Life Sci 1996;58:415–9.
11. Markham SM, Dubin NH, Rock JA. The effect of the menstrual cycle
and of decompression stress on arachidonic acid-induced platelet
aggregation and on intrinsic platelet thromboxane production in
women compared with men. Am J Obstet Gynecol 1991;6:1821–9.
12. Faraday N, Goldschmidt-Clermont PJ, Bray P. Gender differences in
platelet GP IIb/IIIa activation. Thromb Haemost 1997;77:748–54.
13. Agarwal KC. Modulation of vasopressin actions on human platelets by
plasma adenosine and theophylline: gender differences. J Cardiovasc
Pharmacol 1993;21:1012–8.
14. EPIC Investigators. Use of a monoclonal antibody directed against the
platelet glycoprotein IIb/IIIa receptor in high-risk coronary angio-
plasty. N Engl J Med 1994;330:956–61.
15. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor block-
ade and low-dose heparin during percutaneous coronary revasculariza-
tion. N Engl J Med 1997;336:1689–96.
16. EPISTENT Investigators. Enhancement of the safety of coronary
stenting with the use of abciximab, a platelet glycoprotein IIb/IIIa
inhibitor. Lancet 1998;352:87–92.
17. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in
Myocardial Infarction (TIMI) Trial, phase I: a comparison between
intravenous tissue plasminogen activator and intravenous streptoki-
nase: clinical findings through hospital discharge. Circulation 1987;
76:142–54.
18. Muller DW, Sharmir KJ, Ellis SG, Topol EJ. Peripheral vascular
complications after conventional and complex percutaneous coronary
intervention procedures. Am J Cardiol 1992;69:63–8.
19. Granger CB, Hirsh J, Califf RD. Activated partial thromboplastin
time and outcome after thrombolytic therapy for acute myocardial
infarction: results from the GUSTO-I trial. Circulation 1996;93:
870–8.
20. Lefkovits J, Topol EJ. Advances in antiplatelet therapy for acute
cardiovascular disease. In: Topol EJ, editor. Acute Coronary Syn-
dromes. New York: Marcel Dekker, 1998:327–60.
21. Goldschmidt-Clermont PJ, Schulman SP, Bray PF, et al. Refining the
treatment of women with unstable angina—a randomized, double-
blind, comparative safety and efficacy evaluation of integrelin vs.
aspirin in the management of unstable angina. Clin Cardiol 1996;19:
869–74.
22. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa
with eptifibatide in patients with acute coronary syndromes. N Engl
J Med 1998;339:436–43.
23. The Platelet Receptor Inhibition in Ischemic Syndrome Management
Study Investigators. A comparison of aspirin plus tirofiban with aspirin
plus heparin for unstable angina. N Engl J Med 1998;338:1498–505.
24. The Platelet Receptor Inhibition in Ischemic Syndrome Management
in Patients Limited by Unstable Signs and Symptoms (PRISM-
PLUS) Study Investigators. Inhibition of the platelet glycoprotein
IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave
myocardial infarction. N Engl J Med 1998;338:1488–97.
25. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary
syndrome events in a Global Organization Network (PARAGON)
Investigators. International, randomized, controlled trial of Lamifiban
(a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable
angina. Circulation 1998;97:2386–95.
386 Cho et al. JACC Vol. 36, No. 2, 2000
Women and Abciximab August 2000:381–6
